Publications by authors named "Ellen L Verner"
Introduction: Next-generation sequencing (NGS) is currently widely used for biomarker studies and molecular profiling to identify concurrent alterations that can lead to the better characterization of a tumor's molecular landscape. However, further evaluation of technical aspects related to the detection of gene rearrangements and copy number alterations is warranted.
Methods: There were 12 rearrangement-positive tumor specimens from patients with non-small cell lung cancer (NSCLC) previously detected via fluorescence hybridization (FISH), immunohistochemistry (IHC), and an RNA-based NGS assay, and 26 high gene copy number (GCN) cases detected by FISH, selected for this retrospective study.
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing is a complementary approach to tissue testing, particularly when tissue is not readily available. The Labcorp Plasma Focus test is a circulating cell-free DNA genomic profiling test that identifies actionable variants in solid cancers, including non-small-cell lung, colorectal, melanoma, breast, esophageal, gastroesophageal junction, and gastric cancers.
View Article and Find Full Text PDFArticle Synopsis
- Microsatellite instability (MSI) and high tumor mutation burden (TMB-High) are important biomarkers for selecting cancer patients for immune checkpoint therapy, but real-time sequencing can be difficult for advanced cancers.
- A new noninvasive method was developed that uses a specialized gene panel and advanced algorithms to detect MSI and TMB-High from circulating cell-free DNA (cfDNA) in patients.
- The study found that this approach has high specificity and variable sensitivity in detecting MSI and TMB-High, and it can effectively predict treatment outcomes for patients undergoing PD-1 blockade therapy.